WASHINGTON, DC – The Energy and Commerce Committee, chaired by Rep. Greg Walden (R-OR), today held a markup on four bipartisan public bills, including H.R. 2430, the FDA Reauthorization Act (FDARA) of 2017. The #FullCmte also passed 11 bills originating from #SubEnergy to advance the nation’s energy infrastructure and improve energy efficiency.
#FullCmte advanced the following bills:
- H.R. 2430, the FDA Reauthorization Act (FDARA) of 2017, authored by full committee Chairman Greg Walden (R-OR), full committee Ranking Member Frank Pallone, Jr. (D-NJ), Health Subcommittee Chairman Michael C. Burgess, M.D. (R-TX), and Health Subcommittee Ranking Member Gene Green (D-TX), would reauthorize FDA’s critical user fee programs, ensuring the agency has the tools they need to deliver safe and effective drugs, devices, and treatments, to patients more swiftly. Six amendments to H.R. 2430 passed. Adopted amendments were offered by: Chairman Walden; Rep. Ryan Costello (R-PA) and Rep. Scott Peters (D-CA), Rep. Peters and Rep. Costello; Rep. Mimi Walters (R-CA); Rep. Jan Schakowsky (D-IL) #1; Rep. Schakowsky #2. H.R. 2430, as amended, passed by a unanimous vote of 54-0.
- H.R. 1222, the Congenital Heart Futures Reauthorization Act of 2017, authored by Rep. Gus Bilirakis (R-FL) would enhance research and surveillance at the CDC, award grants to further study Congenital Heart Disease, and direct the NIH to report on their ongoing research efforts. H.R. 1222 passed unanimously by voice vote.
- H.R. 2410, the Sickle Cell Disease Research, Surveillance, Prevention and Treatment Act of 2017, authored by Rep. Danny Davis (D-IL) and Health Subcommittee Chairman Michael C. Burgess, M.D. (R-TX), would reauthorize the sickle cell disease prevention and treatment demonstration program. H.R. 2410 passed unanimously by voice vote.
- H.R. 1492, the Medical Controlled Substances Transportation Act of 2017, authored by Rep. Pete Sessions (R-TX), is a revised version of H.R. 3014 in the 114th Congress, which passed by voice vote out of the committee. H.R. 1492 would update the Drug Enforcement Administration registration process for mobile medical practitioners like EMS personnel and team physicians to ensure these health care providers can administer controlled substances at locations other than their principal places of business while complying with new limitations on the timing of transport and related recordkeeping requirements. H.R. 1492 passed unanimously by voice vote.
“FDARA would reauthorize the agency’s critically important drug and medical device user fee programs, making improvements to each of them based on lengthy deliberations involving FDA, industry, patient groups, and other stakeholders,” said Chairman Walden. “As I have said before in this room, if we do not have this bill to the President’s desk in July, not only will thousands of FDA employees be seeking new employment, but desperately needed treatments and cures will not reach patients. We cannot – and will not – stand for that.”
For more information on today’s markup, including a background memo, archived webcast, and text of the legislation, click here.